168 related articles for article (PubMed ID: 12599583)
1. [Therapy for hormone-refractory prostate cancer].
Nishimura K; Takahara S; Nonomura N; Okuyama A
Nihon Rinsho; 2002 Dec; 60 Suppl 11():266-71. PubMed ID: 12599583
[No Abstract] [Full Text] [Related]
2. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
Petrylak DP; Macarthur R; O'Connor J; Shelton G; Weitzman A; Judge T; England-Owen C; Zuech N; Pfaff C; Newhouse J; Bagiella E; Hetjan D; Sawczuk I; Benson M; Olsson C
Semin Oncol; 1999 Oct; 26(5 Suppl 17):28-33. PubMed ID: 10604266
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Oh WK; Kantoff PW
Semin Oncol; 1999 Oct; 26(5 Suppl 17):49-54. PubMed ID: 10604270
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
[TBL] [Abstract][Full Text] [Related]
7. Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
Kreis W; Budman D
Semin Oncol; 1999 Oct; 26(5 Suppl 17):34-8. PubMed ID: 10604267
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
Sinibaldi VJ; Carducci M; Laufer M; Eisenberger M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):45-8. PubMed ID: 10604269
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Mackler NJ; Pienta KJ; Dunn RL; Cooney KA; Redman BG; Olson KB; Fardig JE; Smith DC
Clin Genitourin Cancer; 2007 Jun; 5(5):318-22. PubMed ID: 17645828
[TBL] [Abstract][Full Text] [Related]
10. [Combined treatment of metastatic hormone-resistant prostate cancer].
Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
[No Abstract] [Full Text] [Related]
11. Therapy tolerance in selected patients with androgen-independent prostate cancer following strontium-89 combined with chemotherapy.
Tu SM; Kim J; Pagliaro LC; Vakar-Lopez F; Wong FC; Wen S; General R; Podoloff DA; Lin SH; Logothetis CJ
J Clin Oncol; 2005 Nov; 23(31):7904-10. PubMed ID: 16258090
[TBL] [Abstract][Full Text] [Related]
12. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy combination shows efficacy in hormone-refractory prostate cancer.
Oncology (Williston Park); 1999 Jul; 13(7):1014. PubMed ID: 10442347
[No Abstract] [Full Text] [Related]
14. Controversies in chemotherapy of prostate cancer.
Heicappell R
Front Radiat Ther Oncol; 2002; 36():72-80. PubMed ID: 11842757
[No Abstract] [Full Text] [Related]
15. Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
Hudes GR; Obasaju C; Chapman A; Gallo J; McAleer C; Greenberg R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):6-11. PubMed ID: 7597435
[TBL] [Abstract][Full Text] [Related]
16. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
[TBL] [Abstract][Full Text] [Related]
17. Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls.
Syed S
Cancer; 2003 Nov; 98(10):2088-90. PubMed ID: 14601076
[No Abstract] [Full Text] [Related]
18. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer.
Nishimura K; Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Imazu T; Takaha N; Sugao H; Miki T; Okuyama A
Oncology; 2001; 60(1):49-54. PubMed ID: 11150908
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel in the treatment of hormone-refractory prostate cancer.
Smith DC; Pienta KJ
Semin Oncol; 1999 Feb; 26(1 Suppl 2):109-11. PubMed ID: 10190791
[TBL] [Abstract][Full Text] [Related]
20. [Chemotherapy for prostate cancers].
Naito K
Nihon Rinsho; 2002 Dec; 60 Suppl 11():205-10. PubMed ID: 12599572
[No Abstract] [Full Text] [Related]
[Next] [New Search]